INNOTERE
Develops and manufactures 3D-printed resorbable calcium phosphate scaffolds and bone cements for patient-specific bone regeneration implants, enabling minimally invasive treatment of bone defects.
- CEO / Founder
- Sascha Heinemann
- Team Size
- 11-50
- Stage
- Acquired
- Total Funding
- €12.5M
- Latest Round
- Acquired
- Key Investors
- Nivalis Group
Technology & Products
Key Products
INNOTERE Paste-CPC; INNOTERE 3D Scaffolds; Plotter-Paste-CPC; Cell Culture Scaffolds; Veterinary bone substitutes; Hydroxyapatite powders
Technological Advantage
Patented paste formulation and 3D printing process enable precise control over scaffold architecture and resorption rates, protected by 59 patents in tissue engineering and 3D bioprinting.
Differentiation
Value Proposition
Reduces bone implant production time from weeks to days by enabling direct 3D printing of patient-specific scaffolds from CT data, with materials that mimic natural bone structure and resorb over time.
How They Differentiate
Focuses exclusively on calcium phosphate-based biomaterials for bone regeneration, unlike broader 3D printing companies; offers certified Class III medical devices with MDR 2017/745 certification.
Market & Competition
Target Customers
Hospitals, orthopedic surgeons, veterinary clinics, biomaterials research institutions
Industry Verticals
Medical Devices; Orthopedics; Veterinary Medicine; Biomaterials Research
Competitors
Zimmer Biomet, Stryker, Medtronic, Johnson & Johnson, Geistlich Pharma AG, Xtant Medical
Growth & Milestones
Major Milestones
Founded in 2004; ISO 9001:2008 and ISO 13485:2012 certification in 2008; Moved to Radebeul in 2012; Acquired by Heraeus Medical in early 2025
Notable Customers
Biomaterials research community; Veterinary clinics; Orthopedic hospitals